Abata Therapeutics
Fang Xia has a solid background in the biopharmaceutical industry, starting as a Research Technician at Harvard University in 2009, and progressing to roles at CRISPR Therapeutics, Takeda, and currently at Abata Therapeutics as a Principal Scientist. They have experience in cell therapy process development, CMC, and tech ops, with a focus on research and development in various scientific roles.
Fang Xia attended Harvard University for an unspecified period of time, but the specific degree, field of study, start, and end years are unknown.